
Pembrolizumab





SCORE			
CURATIVE			
Overall Survival / Diseas	se-Free Survival / Patho	logical Complete Resp	onse
NON-CURATIVE			
Overall Survival			
•	2		
Progression-Free Surviv	val		
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate			
Overall Response Rate	/ Duration of Response		

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: EMA: Pembrolizumab for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥1. FDA: Pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1). Experimental Arm: Pembrolizumab + Trastuzumab, fluoropyrimidine + platinumcontaining ChT

Control Arm: Placebo + trastuzumab, fluoropyrimidine + platinum-containing ChT



© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.